F‑Star provides a proprietary antibody engineering platform that creates tetravalent, bispecific and trispecific IgG‑like biologics for oncology and immuno‑oncology applications. The technology enables simultaneous engagement of multiple tumor antigens with native IgG pharmacokinetics, Fc‑engineered half‑life extension, and scalable cGMP manufacturing, delivering higher potency and reduced resistance risk for pharma and biotech partners.
Funding
$65M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current antibody therapeutics often target a single antigen, limiting their ability to address heterogeneous tumor biology and leading to suboptimal efficacy in many oncology and immuno‑oncology indications. Patients with advanced or treatment‑resistant cancers therefore have limited therapeutic options.
Solution
F‑Star applies its proprietary tetravalent and bivalent antibody platforms to engineer bispecific and trispecific biologics that can simultaneously engage multiple disease‑relevant targets. By combining distinct binding specificities within a single molecule, the company aims to improve tumor cell killing, modulate the immune microenvironment, and reduce the likelihood of resistance. The engineered antibodies retain native IgG pharmacokinetics while offering enhanced potency and safety profiles. F‑Star advances these candidates through preclinical validation into clinical‑stage programs, providing a pipeline of next‑generation immunotherapies for hard‑to‑treat cancers.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology or immuno‑oncology programs, as well as clinical research organizations seeking advanced multi‑specific antibody candidates for clinical evaluation.
Features
- Tetravalent platform delivering four independent binding sites within a single IgG‑like scaffold for high‑avidity multi‑target engagement
- Bivalent platform enabling precise pairing of two distinct antigen‑binding domains with optimized geometry
- Modular cloning and expression system that accelerates the design‑build‑test cycle for bispecific and trispecific formats
- Fc engineering for extended half‑life, controlled effector function, and reduced immunogenicity
- Integrated analytical pipeline (SPR, bio‑layer interferometry, cell‑based assays) to quantify simultaneous target binding and functional activity
- Scalable CHO‑cell manufacturing process compliant with cGMP standards, supporting clinical‑grade production
- Early‑stage clinical data generation framework, including adaptive trial designs and biomarker‑driven patient selection